Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652538 | 0.81 | SMO (0.45) | SMOCNR1 | |
| SCHEMBL5653521 | 0.81 | SLC6A7 (0.47) | SMO | |
| SCHEMBL5654206 | 0.80 | FASN (0.41) | SMOCNR1 | |
| SCHEMBL5652861 | 0.80 | SMO (0.46) | SMO | |
| SCHEMBL14366931 | 0.80 | MMP8 (0.52) | SMO | |
| SCHEMBL5656800 | 0.80 | SMO (0.44) | SMO | |
| SCHEMBL14366928 | 0.79 | MAPT (0.42) | SMO | |
| SCHEMBL5654070 | 0.79 | GRM5 (0.45) | SMOCNR1 | |
| SCHEMBL14366961 | 0.79 | MAPT (0.42) | SMO | |
| SCHEMBL5654387 | 0.79 | SMO (0.41) | SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | TRIMERIS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | TRIMERIS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | TRIMERIS, INC. | 2007-11-08 | — | — | US | disclosed |
| WO-2007103456-A2 | PIPERAZINE AND PIPERIDINE BIARYL DERIVATIVES | TRIMERIS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | CYP3A5, CYP3A43, CCR5 | SMO 3378/4885CNR1 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.